此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

体内CAR-T疗法治疗复发/难治性血液恶性肿瘤

2026年11月2日 更新者:Chongqing Precision Biotech Co., Ltd

In Vivo-Generated Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed or Refractory Hematologic Malignancies

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.

It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

研究概览

详细说明

This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell(CAR-T cell) therapy in patients with relapsed refractory malignant hematological tumors. Upon enrollment, subjects will receive an intravenous infusion of the in Vivo CAR-T preparation. Following the infusion, subjects will be hospitalized for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Yunnan
      • Kunming、Yunnan、中国
        • 招聘中
        • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
        • 接触:
        • 接触:
          • Sanbin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age ≥ 18 years old, gender unrestricted;

  2. Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;

  3. ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;

  4. Blood routine test results during the screening period meet the following criteria:

    ① Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin (rhEPO) is allowed; for patients meeting the hemoglobin ≥ 6 g/dL criterion, red blood cell transfusion can be used to maintain hemoglobin ≥ 6 g/dL;

    • Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor [G-CSF] within 1 week before screening, or no use of pegylated G-CSF within 2 weeks before screening); ③ Platelet count ≥ 50,000/μL; ④ Lymphocyte count ≥ 500/μL;
  5. Normal renal function during the screening period: creatinine clearance rate (CrCl) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula);

  6. Liver function during the screening period meets the following criteria:

    ① Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3.0 × ULN;

    ② Total bilirubin (TBIL) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia such as Gilbert's syndrome, direct bilirubin can be relaxed to ≤ 1.5 × ULN);

  7. Cardiac function during the screening period meets the following criteria:

    ① Left ventricular ejection fraction (LVEF) ≥ 40% (measured by echocardiography or MUGA scan);

    ② No clinically significant pericardial effusion;

    ③ No clinically significant electrocardiogram (ECG) abnormalities;

  8. Pulmonary function during the screening period meets the following criteria: blood oxygen saturation (SpO₂) ≥ 90%;

  9. Women of childbearing age must have a negative pregnancy test during the screening period and before drug administration, and must not be in the lactation period;

  10. Men and women of childbearing age must agree to take effective contraceptive measures and not donate reproductive cells (including sperm or eggs) from the time of signing the informed consent form until 1 year after the end of study drug administration;

  11. The subject or their legally authorized representative has signed the informed consent form (ICF), indicating their understanding of the purpose and procedures of the study and their voluntary participation in this study.

Exclusion Criteria:

  1. Other anti-tumor treatments within the screening period (judged by the investigator comprehensively):

    ① Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration;

    ② Received radiotherapy within 4 weeks before administration (if the radiotherapy target area covers ≤ 5% of bone marrow reserve, the time limit for radiotherapy completion is not restricted);

  2. History of hematopoietic stem cell transplantation: Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration;

  3. History of other malignant tumors (except for this disease), except for the following situations:

    ① Received radical treatment and had no known active disease for ≥ 2 years before enrollment;

    ② Had fully treated non-melanoma skin cancer in the past and had no active lesions at present;

  4. Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past;

  5. Had severe and uncontrolled infections (bacterial, viral, fungal, etc.) within the screening period;

  6. Clinically significant cardiac diseases:

    • Had symptomatic heart failure or other serious cardiac diseases (such as severe arrhythmia);

      • Had New York Heart Association (NYHA) Class III-IV congestive heart failure; ③ Had a myocardial infarction or received coronary artery bypass grafting (CABG) / coronary artery stent implantation within 6 months before signing the informed consent;

        • Had clinically significant ventricular arrhythmia or a history of unexplained syncope; ⑤ Had a history of syncope (excluding cases caused by vasovagal reactions or dehydration); ⑥ Had a history of severe non-ischemic cardiomyopathy;
  7. Other clinically significant diseases, including but not limited to:

    • Primary immunodeficiency; ② Had a stroke or seizure within 6 months before screening;

      • Had clear clinical evidence of dementia or mental status changes; ④ Had Parkinson's disease, Parkinson-like movement disorders or a history of the above;
  8. Had undergone surgery within 2 weeks before administration, or planned to undergo surgery within 2 weeks after administration (local anesthesia surgery excluded);

  9. Had received live attenuated vaccines within 1 month before administration;

  10. Had a history of severe allergic reactions to this product or its formulation components;

  11. Patients who were not suitable for establishing intravenous access;

  12. The investigator believed that there were other conditions that made the patient unsuitable for participating in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:体内CAR-T

Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximal Tolerated Dose(MTD)
大体时间:Up to 28 days after infusion

MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment.

Up to 28 days after infusion
Incidence of adverse events(AE) after infusion
大体时间:Up to 28 days after infusion

The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.

Up to 28 days after infusion

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate
大体时间:Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24

Objective Response Rate(ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR).

Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Wang Sanbin, MD、920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年7月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2025年11月16日

首先提交符合 QC 标准的

2025年11月16日

首次发布 (实际的)

2025年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2025年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅